Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Favipiravir for Moderate COVID-19
NCT04425460Phase 3Unknown
- Sponsor
- Zhejiang Hisun Pharmaceutical Co., Ltd.
- Start
- Jun 2020
- Primary completion
- Aug 2020
- Modality
- Small Molecules
- Countries
- 3
01
Overview
Phase 3, randomised, double-blind trial of favipiravir in coronavirus disease 2019 (COVID-19), sponsored by Zhejiang Hisun Pharmaceutical Co., Ltd. Primary endpoint: Time from randomization to clinical recovery at 28 days. Status: unknown.
02
Drugs
favipiravir
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04425460.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04425460.